CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED SHARES AND STOCKHOLDERS' EQUITY (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Payment of offering costs	$ 248	$ 953
Series C Preferred Stock [Member] | Maximum [Member]
Payment of offering costs		100
Series D Preferred Stock [Member]
Payments of financing costs		200
Common Stock [Member]
Payment of offering costs		$ 700
Common Stock [Member] | Pfizer Purchase Agreement [Member]
Payments of financing costs	200
Premium on issued of common stock	$ 12,500